The Transition to Factor XI Inhibitors When you look at the sheer numbers, the global Anticoagulation Market is standing on the precipice of a "safety revolution." In 2026, the industry is moving beyond traditional DOACs (Direct Oral Anticoagulants) toward "Factor XI Inhibitors." These new-generation drugs promise to prevent dangerous blood clots without the significant bleeding risks associated with older medications like...